Hepatitis E News and Research

RSS

Hepatitis E is a viral hepatitis (liver inflammation) caused by infection with a virus called hepatitis E virus (HEV).

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer.

4 Nov 2013

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

Infants who get hepatitis C from their mothers during childbirth may inherit a viral strain that replicates more quickly than strains found in non-pregnant hosts, according to a new study published Oct. 27 in Nature Medicine.

29 Oct 2013

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

In a move to address a significant unmet need in hepatitis C in Canada, the University Health Network, together with Boehringer Ingelheim (Canada) Ltd., announced today a multi-year partnership that aims to improve care, education and support for patients with hepatitis C. The program, known as Link-C, aims to improve access to hepatitis C care and treatment in remote areas of Ontario and other parts of Canada.

23 Oct 2013

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration has granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment of chronic hepatitis C virus infection.

23 Oct 2013

Three cups of coffee per day reduce liver cancer risk by more than 50%

Coffee consumption reduces risk of hepatocellular carcinoma (HCC), the most common type of liver cancer, by about 40 percent, according to an up-to-date meta-analysis published in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

23 Oct 2013

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

University of Sydney researchers are currently surveying community pharmacists and dentists to gauge their support to introduce rapid HIV and STI testing in pharmacies and dental surgeries, potentially increasing rates of early diagnosis.

22 Oct 2013

Medmira Wins Additional $1.9M Army Contract

...

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

HBV-infected men more likely to develop liver cancer

A team of researchers has identified a novel mutation in the hepatitis B virus (HBV) in Korea that appears only in men and could help explain why HBV-infected men are roughly five times more likely than HBV-infected women to develop liver cancer.

18 Oct 2013

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

For the first time, researchers at the University of California, San Diego School of Medicine have isolated and characterized the progenitor cells that eventually give rise to malignant hepatocellular carcinoma tumors - the most common form of liver cancer. The researchers found ways to identify and isolate the HCC progenitor cells long before actual tumors were apparent.

11 Oct 2013

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

The addition of danoprevir to the current treatment regimen for patients with hepatitis C leads to high rates of remission, according to a new article in Gastroenterology, the official journal of the American Gastroenterological Association.

11 Oct 2013

Patients who received care at multiple HIV clinics have higher HIV viral loads

Patients who received care at multiple HIV clinics—as opposed to only one— were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Receiving care at several HIV clinics may increase medication errors

Patients who received care at multiple HIV clinics-as opposed to only one- were less likely to take their medication and had higher HIV viral loads, a new study published in the journal AIDS and Behavior of almost 13,000 HIV patients in Philadelphia from Penn Medicine found.

10 Oct 2013

Research on flaviviruses could help in developing effective therapies for persistent infections

We generally do not devote much time to worrying about the problems faced by viruses, although understanding them may provide clues on how to combat diseases.

9 Oct 2013

Researchers recently launched Collaborative Hepatitis Network in Africa

Although it does not receive as much attention as AIDS, hepatitis has long been one of Africa's most serious health problems.

9 Oct 2013

Healthcare providers report unaccompanied teens may not receive required vaccines

Healthcare providers report that older teens often go to the doctor without a parent or guardian, a new survey in the Journal of Adolescent Health reveals—and those teens may not get necessary vaccinations because there's no parent or guardian present to give consent.

9 Oct 2013

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc.

9 Oct 2013

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

A major study conducted at the Sahlgrenska Academy has now disproved theories of a viral cause for breast cancer and the brain tumour, glioblastoma. The study, which was based on over seven billion DNA sequences and which is published in Nature Communications, found no genetic traces of viruses in these forms of cancer.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Hepatitis E News and Research

Further Reading

Scientists make seminal breakthrough in understanding molecular basis of bile duct cancer

Infants who get hepatitis C from mothers during childbirth may inherit viral strain

UHN, Boehringer Ingelheim partner to improve care, education and support for hepatitis C patients

FDA grants Breakthrough Therapy designation to MK-5172/MK-8742 for chronic HCV infection

Three cups of coffee per day reduce liver cancer risk by more than 50%

Sydney researchers plan to introduce rapid HIV and STI testing in pharmacies, dental surgeries

Medmira Wins Additional $1.9M Army Contract

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

HBV-infected men more likely to develop liver cancer

Researchers find ways to identify, isolate HCC progenitor cells before tumors become evident

Adding danoprevir to treatment regimen for hepatitis C patients leads to high rates of remission

Patients who received care at multiple HIV clinics have higher HIV viral loads

Receiving care at several HIV clinics may increase medication errors

Research on flaviviruses could help in developing effective therapies for persistent infections

Researchers recently launched Collaborative Hepatitis Network in Africa

Healthcare providers report unaccompanied teens may not receive required vaccines

Janssen buys all rights from GSK to develop, commercialize hepatitis C compound

Sahlgrenska Academy study finds no traces of viruses in breast cancer and glioblastoma

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News